

Date: 14th November, 2025

To

Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

Scrip Code: 542248

Subject: Outcome of Board Meeting held on today i.e. 14th November, 2025 in terms of second proviso to

Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam

With reference to our Intimation vide letter dated Monday, 10th November 2025 we wish to inform you that the Board Directors of the Company in its meeting held today i.e. Friday, 14th November 2025 through Video Conferencing have Inter-alia;

- 1. Considered and Approved the Standalone Unaudited Financial Results of the Company for the quarter ended 30th September, 2025 along with the Limited Review Report.
- 2. Considered and Approved the Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th September, 2025 along with the Limited Review Report.
- 3. Mr. Mohak Gupta, Director of the company is authorized to sign the financial Result for the quarter ended 30th September, 2025.

Further the said outcome shall be uploaded on the website of the company at www.deccanhealthcare.co.in.

Details as required under regulation 30 of listing regulations read with SEBI circular SEBI/HO/CFD/CFDPoD 1/P/CIR/2023/123 dated July 13, 2023 are provided herewith.

The meeting was commenced at 03:00 P.M. and concluded at 03:16 P.M.

You are requested to take the information on record and oblige.

Thanking You,
Yours faithfully
For Deccan Health Care Limited

Ronak Darji Company Secretary & Compliance Officer (M. No. A67434)

Registered Office: 6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Punjagutta, Hyderabad – 500082, Telangana, India Email: info@deccanhealthcare.co.in

Tel: +91 40 4709 6427

Innovation Hub & Manufacturing: Plot No.13, Sector 03, IIE Pant Nagar, SIDCUL, Udham Singh Nagar – 263153, Uttarakhand, India CIN: L72200TG1996PLC024351

www.deccanhealthcare.co.in



Date: 14th November, 2025

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001, Maharastra

Stock Code: 542248

<u>Subject: Submission of Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter</u> ended on 30th September, 2025 along with Limited Review Reports issued by Statutory Auditors

Dear Sir/Madam

With reference to above captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th September, 2025 along with the Limited Review Report issued by Statutory Auditors.

The said financial results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

We request you to take the same on records.

Thanking You,
Yours Faithfully,
For and on behalf of
Deccan Health Care Limited

Ronak Darji Company Secretary & Compliance Officer (M. No. A67434)

Encl: a/a

Registered Office: 6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Punjagutta, Hyderabad – 500082, Telangana, India Email: info@deccanhealthcare.co.in

Tel: +91 40 4709 6427

Innovation Hub & Manufacturing: Plot No.13, Sector 03, IIE Pant Nagar, SIDCUL, Udham Singh Nagar – 263153, Uttarakhand, India CIN: L72200TG1996PLC024351

www.deccanhealthcare.co.in



CA Keyur Shah FCA, B.Com, ISA, FAFP Certified

Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results of the Company for the quarter and half year ended 30th Sept., 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,

The Board of Directors of,

Deccan Health Care Limited

We have reviewed the accompanying the statement of unaudited standalone financial results of **Deccan Health Care Limited** for the Quarter and Half year ended **30**th **Sept., 2025** attached herewith, being submitted by the company pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement, which is the responsibility of the Company Management and approved by the Company Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting standard ("Ind AS") and other recognized accounting practices and policies as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Associates

SHAH & ASSOC

Chartered Accountants

F.R.No. 333288W

Akhlaq Ahmed Mutvalli

Partner

M. No. 181329

UDIN: -25181329BMHCDI6777

Date: - 14th November, 2025

Place: - Ahmedabad



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Standalone financial Results for the Quarter And Half Year Ended on 30th Sept., 2025

			Rs. in	Lakhs (unless	otherwise stat	ted)		
_		0	uarter Ended		Half Year	Ended	Year Ended	
Sr. No.	Particulars	30th Sept., 2025	30th June, 2025	30th Sept., 2024	30th Sept., 2025	30th Sept., 2024	31st March, 2025	
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	
1	Income From Operations		Committee of the Commit					
	a) Revenue from Operations	2,440.46	2,146.95	1,882.08	4,587.41	3,388.19	7,513.19	
	b) Other Income	0.13	0.62	0.11	0.75	0.11	0.57	
	Total Income	2,440.59	2,147.57	1,882.19	4,588.16	3,388.30	7,513.76	
11	Expenses							
	a) Cost of Materials Consumed	1,583.17	1,905.21	1,075.11	3,488.38	1,704.89	4,096.37	
	 b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade 	9.42	(361.27)	61.35	(351.85)	306.64	660.78	
	c) Employee Benefit Expense	144.67	136.37	130.06	281.04	220.90	434.82	
	d) Finance Costs	16.43	1.71	2.51	18.14	4.16	7.39	
	e) Depreciation and Amortisation Expense	32.72	40.55	36.66	73.27	72.68	145.26	
	f) Other Expenses	532.25	394.89	504.66	927.14	957.90	2,002.22	
	Total Expenses	2,318.66	2,117.46	1,810.35	4,436.12	3,267.17	7,346.84	
Ш	Profit/ (Loss) Before Tax (I-II)	121.93	30.11	71.84	152,04	121.13	166.92	
IV	Tax Expense							
	a) Current Tax	34.58	13.17	21.62	47.75	37.49	57.01	
	b) Deferred Tax (Asset)/Liabilities	(2.62)	(4.31)		The section of the se	(6.98)	(9.88)	
	Total Tax Expense	31.96	8.86	18.11	40.82	30.51	47.13	
٧	Net Profit/ (Loss) After Tax for the Period	89.97	21.25	53.73	111.22	90.62	119.79	
VI	(III-IV) Other Comprehensive Income/ (Loss)	3.81	3.80	(0.03	7.61	(0.04)	15.22	
	a) Items that will not be reclassified to Profit	3.01	3.00	(0.00				
نسادت	& Loss (Net Of Tax) b) Items that may be reclassified to Profit			-		-		
	& Loss (Net Of Tax)	3.81	3.80	(0.03	7.61	(0.04)	15,22	
10000000	Total Other Comprehensive Income/ (Loss)	20.70	25.05	53.70	118.83	90.58	135.01	
VII	Total Comprehensive Income/ (Loss) for the period (V + VI)			2 208 05	2,474.92	2,098.05	2,342.55	
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,474.92	2,474.92	2,098.05	2,474.72	2,070.00		
	4						8,312.66	
IX	Other Equity Earnings Per Equity Share- Basic/Diluted						4 0.56	
X	PA PA	0.36	0.0		THE RESERVE AND A STREET			
	Basic Diluted (After conversion of warrants)	0.30	0.0	9 0.21	0.4	5 0.3	0 0,47	

For, Deccan Health Care Limited

Date: 14th November, 2025

Place: Hyderabad

Mohak Gupta
Whole-time director
(DIN: 03534904)



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Notes to Accounts -Standalone Financial Statement

[1] The above un-audited standalone financial results for the quarter ended 30th Sept., 2025 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 14th November, 2025. A limited review of the above results has been carried out by the statutory auditors of the company.

- [2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.
- [3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act, 2013.
- [4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.
- [5] The Figure for the quarter ended 30th Sept., 2025 are balancing figures between the un-audited figures in respect of half year ended on 30th Sept., 2025 and the quarter figures up to the first quarter ended on 30th June, 2025, which were subject to limited review.
- [6] The Status of investor's complaints during the quarter ended on 30th Sept. 2025 as under:-

Nil
MIL
Nil
Nil
Nil
MIL

For, Deccan Health Care Limited

Mohak Gupta Whole-time director

(DIN: 03534904)

Date: 14th November, 2025

Place: Hyderabad



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Standalone Balance Sheet As At 30th Sept., 2025

		Rs. in Lakhs (unless otherwise stated) As at		
Sr.	Particulars			
No.	raiticulars	30th Sept.,2025	31st March 2025	
		Un-audited	Audited	
1	ASSETS			
A	Non-Current Assets			
	a) Property Plant & Equipments	1,367.60	1,436.63	
	b) Intangible Assets	1.72	1.72	
	c) Financial Assets	Company of the property of the contract of the		
	- Investments	1.00	1.00	
	- Other Financial assets & Loans	178.64	193.03	
	d) Other Non-Current Assets	237.35	236.92	
	Total Non-Current Assets	1,786.31	1,869.30	
В	Current Assets			
_	a) Inventories	4,323.39	4,253.05	
	b) Financial Assets		· ·	
	- Trade receivables	1,661.58	1,261.42	
	- Cash and Cash Equivalents	185.38	348.94	
	- Other Bank Balances	2.06		
	- Other Financial assets & Loans	145.02	211.59	
	c) Other Current Assets	5,515.71	4,448.76	
	Total Current Assets	11,833.14	10,523.76	
	TOTAL ASSETS	13,619.45	12,393.06	
11	EQUITY AND LIABILITIES			
1				
- die	a) Equity Share capital	2,474.92	2,342.55	
	b) Other Equity - attributable to owners of the company	8,420.89	8,312.66	
	TOTAL EQUITY	10,895.81	10,655.21	
2	LIABILITIES			
Ā		A CONTRACTOR OF THE CONTRACTOR		
	a) Financial Liabilities	MANERAL DEL CALLERS CONTROL	00 42	
	- Long Term Borrowings	78.62	88.43 25.39	
	b) Long Term Provisions	33.90	170.10	
	c) Deferred Tax Liabilities (Net)	160.62	283.92	
	Total Non-Current Liabilities	273.14	203.72	



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Standalone Balance Sheet As At 30th Sept., 2025

Sr.		Rs. in Lakhs (unless	otherwise stated)	
No.	Particulars	As at		
10.		30th Sept.,2025	31st March 2025	
В	Command Red Street	Un-audited	Audited	
D	Current liabilities			
	a) Financial Liabilities	and the second section of the second		
	- Short Term Borrowings	53.51	26 42	
	- Trade payables		26.12	
	(i) Total outstanding dues of other than Micro	1,602.55	950 05	
	(11) Total outstanding dues of Micro Enterprise and	41.79	850.95 41.79	
	- Other Financial Liabilities b) Short-Term Provisions	266.22	213.27	
		48.74	26.03	
	c) Other Current Liabilities	247.33	155.29	
	d) Current Tax Liabilities (Net)	190.36		
	Total Current Liabilities	2,450.50	140.48	
			1,453.93	
	TOTAL LIABILITIES	2,723.64	1,737.85	
	TOTAL EQUITY AND LIABILITIES	13,619.45	12,393.06	

For, Deccan Health Care Limited,

Date:14th November, 2025

Place :- Hyderabad

Mohak Gupta

Whole-time director

(DIN: 03534904)



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Standalone Cash Flow Statement for the Half Year Ended 30th Sept., 2025

		Rs. in Lakhs (unless otherwise stated) Half Year Ended		
Sr.	Particulars			
No.	Particulars	30th Sept., 2025	30th Sept., 2024	
		Un-audited	Unaudited	
A.	CASH FLOW FROM OPERATING ACTIVITIES			
	Net profit Before Tax and Extraordinary Iteams	152.04	121.13	
	Adjustments For:			
	Depreciation	73.27	72.68	
	Interest Received	(0.75)	(0.05	
	Interest and Finance Charges	18.14	4.16	
	Adjustment related to OCI effect	(10.17)	(0.11)	
	Provision For Gratuity	3.49	1.59	
	Operating profit/(loss) before working capital changes	236.02	199.40	
	Changes in working capital:			
	Adjustments for (increase) / decrease in operating assets:			
	Changes in Inventories	(70.33)	145.20	
	Changes in Trade receivables	(400.15)	(15.03)	
	Changes in Other Financial Asset	66.57	(58.00)	
	Changes in Other Current Asset	(1,066.92)	(714.70)	
	Changes in Trade Payables	751.60	212.50	
	Changes in Other Financial Liabilities	52.95	53.28	
	Changes in Other Current Liabilities	92.04	39.34	
	Changes in Current Tax Liabilities	4.26		
	Changes in Long Term Provisions	5.02	-	
	Changes in Short Term Provisions	22.71	80.69	
	Cash generated from operations	(306.23)	(57.32)	
	Income taxes paid (net of refunds)	(2.13)	(85.61)	
	Net cash flow from / (utilised in) operating activities (A)	(308.36)	(142.93)	
В.	CASH FLOW FROM INVESTING ACTIVITIES			
	Interest Received	0.75	0.05	
	(purchase) of fixed assets	(4.24)	(7.15)	
	Changes in Other Bank Balances	(2.06)		
	Net cash flow from / (used in) investing activities (B)	(5.55)	(7.10)	



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG · 500082

Standalone Cash Flow Statement for the Half Year Ended 30th Sept., 2025

		Rs. in Lakhs (unless	otherwise stated)	
Sr.	Danking	Half Yea	ear Ended	
No.	Particulars	30th Sept., 2025	30th Sept., 2024	
		Un-audited	Unaudited	
c.	CASH FLOW FROM FINANCING ACTIVITIES			
	Issue/Conversion Of Shares/share Warrants & Premium	137.00	135.97	
	Changes in Short Term Borrowing	27.41	3.86	
	Interest and Finance Charges	(18.14)	(4.16)	
	Changes in Other Financial Assets & loans and advances	14.39	(0.35)	
	Proceeds from Long Term Borrowing	-	2	
	Repayment of Long Term Borrowing	(10.31)	(17.58)	
	Net cash flow from / (used in) financing activities (C)	150.35	117.74	
D.	Net increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(163.56)	(32.28)	
E.	Opening Balance of Cash and Cash Equivalents	348.94	222.41	
F.		185.38	190.13	

The standalone statement of cash flows has been prepared in accordance with the Indirect method as set out in the Indian Accounting Standard (Ind AS) - 7 - 'Statement of Cash Flows'.

For, Deccan Health Care Limited,

Mohak Gupta

Whole-time director

(DIN: 03534904)

Date: 14th November, 2025

Place:- Hyderabad



CA Keyur Shah FCA, B.Com, ISA, FAFP Certified

Independent Auditor's Limited Review Report on the Unaudited Consolidated Financial Results of the Company for the quarter and half year ended 30th Sept., 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Unaudited Financial Results of **Deccan Health Care Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter and half year ended 30th Sept., 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.

A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



E-mail: keyur@keyurshahca.com, ca.keyurshah2015@gmail.com

The Statement includes the results of the following entities:

1. Beyoungstore Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the statement provided by the Management related to subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes the unaudited interim financial results/ financial information in respect of:

One Subsidiary which has not been reviewed by us, whose unaudited interim financial results reflect total revenue of Rs. 190.72 Lakhs and Rs. 290.04 Lakhs for the quarter and half year ended 30th Sept., 2025, total profit after tax of Rs. 1.43 Lakhs and Rs. 3.89 Lakhs for the quarter and half year ended 30th Sept., 2025 and total Other Comprehensive Income of Rs. 1.43 Lakhs and Rs. 3.89 Lakhs for the quarter and half year ended 30th Sept., 2025 and net cash outflows of Rs. 5.15 Lakhs for the half year ended 30th Sept., 2025, as considered in the Statement. These interim financial results have been reviewed by the subsidiary's independent auditors under generally accepted auditing standards applicable and their review report has been furnished to us by the Management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement is not modified in respect of the above matters.

SHAH & ASSOC

REDACCO

For, Keyur Shah & Associates

Chartered Accountants

F.R.Np. 333288W

Akhlaq Ahmad Mutvalli

Partner

M. No. 181329

UDIN: -25181329BMHCDJ8180

Date: - 14th November, 2025

Place: - Ahmedabad



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Consolidated financial Results for the Quarter And Half Year Ended on 30th Sept., 2025

Rs. in Lakhs (unless otherwise stated) Half Year Ended Year Ended Quarter Ended Sr. **Particulars** 30th Sept.. 30th Sept., 31st March. 30th Sept., 30th Sept., 30th June, No. 2025 2024 2025 2024 2025 2025 Un-audited Audited Un-audited Un-audited Un-audited Un-audited Income From Operations 1 3.388.19 7,505.79 4.353.58 a) Revenue from Operations 2,139,56 2,214.02 1.882.08 0.75 0.11 0.57 b) Other Income 0.11 0.13 0.62 1,882.19 4,354.33 3,388,30 7,506.36 Total Income 2,139,69 2,214.64 Expenses 3,168.19 1,704.89 4.088.97 a) Cost of Materials Consumed 1.075.11 1.256.63 1,911.56 b) Changes in Inventories of Finished Goods. (351.85)306.64 660.78 61.35 9.42 (361.27)Work-In-Progress and Stock-In-Trade 225.67 285.65 444.21 132.39 c) Employee Benefit Expense 146.97 138.68 4.17 2.52 18.15 7.42 d) Finance Costs 1.72 16.43 73.27 72.68 145.26 36.66 e) Depreciation and Amortisation Expense 32.72 40.55 1,004.99 954.65 1,996.70 503.20 f) Other Expenses 554.98 450.01 4,198.40 3,268,70 7,343.34 1,811.23 Total Expenses 2,017,15 2,181.25 70.96 155.93 119.60 163.02 Profit/ (Loss) Before Tax (I-II) 122.54 33.39 111 Tax Expense 47.75 37.49 57.01 21.62 33.76 13.99 a) Current Tax (3.51)(6.93)(6.98)(9.86)b) Deferred Tax (Asset)/Liabilities (2.62)(4.31)30.51 47.15 40.82 18.11 Total Tax Expense 31.14 9.68 89.09 115.87 115.11 52.85 Net Profit/ (Loss) After Tax for the 91.40 23.71 Period (III-IV) Other Comprehensive Income/ (Loss) (0.03)7.61 (0.04)15.22 3.80 a) Items that will not be reclassified to 3.81 Profit & Loss (Net Of Tax) b) Items that may be reclassified to Profit & Loss (Net Of Tax) 15.22 (0.03)7.61 (0.04)3.81 3.80 Total Other Comprehensive Income/ (Loss) 89.05 131.09 27.51 52.82 122.72 95.21 Total Comprehensive Income/ (Loss) for VII the period (V + VI) 2,098.05 2,342.55 2,098.05 2,474.92 2,474.92 2,474.92 Paidup Equity Share Capital (Facevalue Rs 10 each) 8,296.52 Other Equity Earnings Per Equity Share- Basic/Diluted 0.54 0.43 0.10 0.26 0.47 0.37 0.45

0.37

0.10

0.21

For, Deccan Health Care Limited

0.35

Date: 14th November, 2025

Diluted (After conversion of warrants)

Place: Hyderabad

Mohak Gupta Whole-time directo (DIN: 03534904)

0.47



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Notes to Accounts -Consolidated Financial Statement

[1] The above un-audited consolidated financial results for the quarter ended 30th Sept., 2025 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 14th November, 2025. A limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act.2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] The Figure for the quarter ended 30th Sept., 2025 are balancing figures between the un-audited figures in respect of half year ended on 30th Sept., 2025 and the quarter figures up to the first quarter ended on 30th June, 2025, which were subject to limited review.

[6] The Status of investor's complaints during the quarter ended on 30th Sept., 2025 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

For, Deccan Health Care Limited

Mohak Gupta Whole-time directo

(DIN: 03534904)

Date: 14th November, 2025

Place: Hyderabad



3

LIABILITIES

A Non-Current Liabilities a) Financial Liabilities

- Long Term Borrowings

c) Deferred Tax Liabilities (Net)

Total Non-Current Liabilities

b) Long Term Provisions

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

	Consolidated Balance Sheet As At 30	oth Sept., 2025		
		Rs. in Lakhs (unless otherwise stated) As at		
Sr.	Darkinulana			
No.	Particulars	30th Sept.,2025	31st March 2025	
		Un-audited	Audited	
1	ASSETS			
Α	Non-Current Assets			
	a) Property Plant & Equipments	1,367.60	1,436.63	
	b) Intangible Assets	1.72	1.72	
	c) Financial Assets			
	- Other Financial assets & Loans	179.32	193.27	
	d) Other Non-Current Assets	237.35	236.92	
	Total Non-Current Assets	1,785.99	1,868.54	
В	Current Assets	Automotive and the second		
	a) Inventories	4,591.86	4,260.45	
	b) Financial Assets			
	- Trade receivables	1,463.64	1,253.64	
	- Cash and Cash Equivalents	186.68	355.39	
	- Other Bank Balances	2.06		
	- Other Financial assets & Loans	88.98	90.53	
	c) Other Current Assets	5,708.08	4,664.16	
	Total Current Assets	12,041.30	10,624.17	
	TOTAL ASSETS	13,827.29	12,492.71	
11	EQUITY AND LIABILITIES			
1	EQUITY			
-	a) Equity Share capital	2,474.92	2,342.55	
	b) Other Equity - attributable to owners of the company	8,408.65	8,296.52	
	TOTAL EQUITY	10,883.57	10,639.07	
2	Non Controling Interest	A STATE OF THE STA	290	
_	#####################################			

88.43

25.39

170.12

283.94

142.89

33.90

160.62

337.41



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Consolidated Balance Sheet As At 30th Sept., 2025

		Rs. in Lakhs (unless otherwise stated)		
Ś۲۰	Devision 1.	As at		
No.	Particulars	30th Sept.,2025	31st March 2025	
		Un-audited	Audited	
В	Current liabilities			
	a) Financial Liabilities			
	- Short Term Borrowings	53.51	26.12	
	- Trade payables			
	(i) Total outstanding dues of other than Micro	1,620.01	856.13	
	Enterprise and Small Enterprises			
	(ii) Total outstanding dues of Micro Enterprise and	41.78	41.78	
	Small Enterprises			
	- Other Financial Liabilities	266.22	213.27	
	b) Short-Term Provisions	49.23	26.30	
	c) Other Current Liabilities	385.19	265.62	
	d) Current Tax Liabilities (Net)	190.37	140.48	
	Total Current Liabilities	2,606.31	1,569.70	
	TOTAL LIABILITIES	2,943.72	1,853.64	
	TOTAL EQUITY AND LIABILITIES	13,827.29	12,492.71	

For, Deccan Health Care Limited,

Mohak Gupta

Whole-time director*

(DIN: 03534904)

Date: 14th November, 2025

Place :- Hyderabad



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Consolidated Cash Flow Statement for the Half Year Ended 30th Sept., 2025

Rs. in Lakhs (unless otherwise stated) Half Year Ended Sr. **Particulars** 30th Sept., 2024 30th Sept., 2025 No. Unaudited Un-audited A. CASH FLOW FROM OPERATING ACTIVITIES 119.60 155.93 Net profit Before Tax and Extraordinary Iteams Adjustments For: 72.68 73.27 Depreciation (0.05)(0.75)Interest Received 4.17 18.15 Interest and Finance Charges (0.11)(10.17)Adjustment related to OCI effect 1.59 3.49 Provision For Gratuity 197.88 239.92 Operating profit/(loss) before working capital changes Changes in working capital: Adjustments for (increase) / decrease in operating assets: 145.20 (331.41)Changes in Inventories (15.03)(210.00)Changes in Trade receivables (15.53)1.55 Changes in Other Financial Asset (727.42)(1,043.93)Changes in Other Current Asset 213.65 763.88 Changes in Trade Payables 53.28 52.95 Changes in Other Financial Liabilities 57.28 119.57 Changes in Other Current Liabilities 5.02 Changes in Long Term Provisions 4.28 Changes in Current Tax Liabilities 80.43 22.93 Changes in Short Term Provisions (0.43)Changes in Non Current Asset (10.26)(375.67)Cash generated from operations (85.61)(2.14)Income taxes paid (net of refunds) (95.87)(377.81)Net cash flow from / (utilised in) operating activities (A) B. CASH FLOW FROM INVESTING ACTIVITIES 0.05 0.75 Interest Received (7.15)(4.24)(purchase) of fixed assets (2.06)Changes in Other Bank Balances

Net cash flow from / (used in) investing activities (B)

(7.10)

(5.55)



CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Punjagutta Hyderabad, TG - 500082

Consolidated Cash Flow Statement for the Half Year Ended 30th Sept., 2025

		Rs. in Lakhs (unless otherwise sta		
C-	Particulars	Half Year Ended		
Sr. No.		30th Sept., 2025	30th Sept., 2024	
NO.		Un-audited	Unaudited	
	CASH FLOW FROM FINANCING ACTIVITIES Issue/Conversion Of Shares/share Warrants & Premium Changes in Short Term Borrowing Interest and Finance Charges Changes in Other Financial Assets & loans and advances Proceeds from Long Term Borrowing Repayment of Long Term Borrowing Net cash flow from / (used in) financing activities (C)	137.00 27.39 (18.15) 13.95 - 54.46 214.65	135.97 3.86 (4.17) (30.98) (66.45) 38.23	
-		(168.71)	(64.73)	
D. Net in	t increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	355.39	260.27	
Ε.	Opening Balance of Cash and Cash Equivalents Closing Balance of Cash and Cash Equivalents	186.68	195.54	

The consolidated statement of cash flows has been prepared in accordance with the Indirect method as set out in the Indian Accounting Standard (Ind AS) - 7 - 'Statement of Cash Flows'.

For, Deccan Health Care Limited,

Mohak Gupta

Whole-time director

(DIN: 03534904)

Date: 14th November, 2025

Place :- Hyderabad